StemCell Therapy

According toBlueWeave Consultingthe globalAI in Healthcare marketis estimated to reach US$ 37.9 Billion by 2026 with a growing CAGR of 52.3 % during the forecast period 2020- 2026. Several factors driving growth are the increasing need to reduce healthcare costs, rising importance of big data in healthcare, increased acceptance of precision medicine and raising hardware costs. Increasing applicability of AI-based software in medical care and growing investment in venture capital can also be attributed to the surge in demand for this technology. For example, Care Predict, Inc. is using AI technology to track changes in behavioral patterns and activity to predict health issues early.

Request to get the report sample pages at :https://www.blueweaveconsulting.com/ai-in-healthcare-market-bwc19396/report-sample

Increasing number of cross-industry partnerships are expected to boost the healthcare sectors adoption of AI, which is further responsible for its lucrative growth rate. GNS Healthcare entered into a cross-industry partnership with Alliance and Amgen in September 2018 to conduct oncology clinical trials. The goal of the collaboration was to use data from clinical trials and Artificial Intelligence (AI) to identify factors that improve treatment responses in patients with metastatic colorectal cancer (CRC).

AI adoption in healthcare is increasing, with an increased focus on improving patient care quality through the use of artificial intelligence in various aspects of healthcare services, such as virtual assistants & surgeries. The AI-based technologies, such as clinical decision support systems & voice recognition software, help streamline hospital workflow procedures, and optimize medical care, thus improving patient experience. Incorporating AI into healthcare has multiple advantages for both patients and healthcare providers. AI, such as, allows personalized treatment, based on health conditions and past medical history. In addition, AI-based software can be used for continuous health monitoring, which in effect can ensure prompt care & treatment and may ultimately decrease hospital stay. On the other side, medical practitioners unwillingness to adopt new technology, a drastic lack of predetermined and uniform regulatory guidelines, a shortage of curated health care data and data privacy issues impede the markets potential to attain higher grounds.

AI-enabled bots are an AI program that patients can communicate with on a website or by telephone via a chat window. Applications such as scheduling appointments; reviewing insurance coverage parameters; quick access to information on drug interactions and side effects; collecting up-to-date information on patient medications, health care staff and recent procedures; designing special diet strategies for nutritional limited patients; and contacting discharged patients to follow up on treatment plans and ads. Such technologies are expected to lead the growth of hospital and inpatient care systems. Furthermore, the growing need for accurate & early diagnosis of chronic diseases and disorders further supports this markets growth. Nevertheless, the reluctance to implement AI technologies among end-users, lack of trust and potential risks associated with AI in the healthcare sector somewhat restrict the growth of this market.

Application for patient management to see significant growth in the market with significant pace in coming years as successful patient management is one of the most important needs for hospital facilities. Several studies have shown how important patient participation is in improving health outcomes. Lack of such participation contributed greatly to preventable deaths. Smart wearables also play a crucial role in transforming the current healthcare sector. Consumers are also becoming more aware of wearables, and many consumers today believe that wearing a smart device that monitors their vitalities will lead to increased average life expectancy.

Request to get the report description pages at :https://www.blueweaveconsulting.com/ai-in-healthcare-market-bwc19396/

Artificial intelligence in healthcare market is fragmented owing to the presence of number of large-sized companies, mid-sized & small-sized companies, and many start-ups that provide artificial intelligence in healthcare industry. However, the companies that hold the majority share of artificial intelligence in healthcare market are NVIDIA, Intel, IBM, Microsoft, Google, Siemens Healthineer, General Electric (GE) Company, Medtronic, Amazon Web Services (AWS), Koninklijke Philips, Johnson & Johnson Services, Butterfly Network, Welltok, Inc., Micron Technology and Other Prominent Players.

About Us

BlueWeave Consultingis a one-stop solution for market intelligence regarding various products and services online & offline. We offer worldwide market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality performance and nourishing the long-lasting relationships with its clients. We are one of the promising digital market intelligence generation company delivering unique solutions for blooming your business and making the morning, more rising & shining.

Contact Us:

[emailprotected]

https://www.blueweaveconsulting.com

Global Contact: +1 866 658 6826,+1 425 320 4776

Read the original:
AI in Healthcare Market projected a CAGR of 52.3% during the forecast period, 2020-2026 - 3rd Watch News

MANOA A new study out of the University of Hawaii at Manoa suggests reef health may largely be dictated by a microscopic turf war between coral and algae, though other environmental factors still impact reefs, such as ocean acidification or excess nutrients.

The study, published in the journal PNAS, was led by researchers at UH and San Diego State University, and found that the outcome of the competition between coral and turf algae is determined by the assemblage of microbes at the interface where the contenders meet, according to a UH press release.

In the release, researchers explain all plants and animals are associated with communities of viruses and microbes their microbiome that interact via a suite of chemicals produced by their metabolism, termed metabolites.

The study investigated the role of each component, host organisms, viruses, bacteria and metabolites, in coral-turf algal interactions. The researchers gathered data on genes, proteins and metabolic products associated with corals and algae on a reef and directly looked at the bacteria and viruses under a microscope.

We found that when coral interacts with turf algae on a reef, there is a unique chemical and bacterial community that forms at the interface between these two organisms, an emergent microbiome, said Ty Roach, postdoctoral researcher at the Hawaii Institute of Marine Biology in the UH School of Ocean and Earth Science and Technology and co-lead author of the study.

This interface community is made up of larger bacterial cells that use energy at a faster rate. Our data suggest that this change in bacterial size and energy use, which can negatively affect coral, is driven by a change in which types of bacteria dominate the microbiome.

Co-lead author Mark Little, a doctoral candidate at SDSU, explained that chemical analysis indicates the change is driven by bacteria that feed on algal-derived biochemicals, a phenomenon called the algal feeding hypothesis.

Interestingly, these changes in bacterial groups and their energy use, which come from feeding on specific chemicals, are similar to changes seen in the human gut, with dominant bacteria linked to obesity, Little said.

Coral reefs are valued for their cultural and ecological importance, providing protection against storms and waves, and serve as reservoirs of biodiversity. Restoring coral cover and building reef resilience provides the foundation essential to a functional and healthy reef ecosystem, which is critical for the surrounding community.

This highlights the fact that many ecological interactions between organisms are actually mediated by viruses and bacteria, said Forest Rohwer, biology professor at SDSU and senior author of the study. This provides opportunities to engineer probiotics to alleviate the effects of stressors on corals.

The research team plans to use the insight gained from this study to design and test probiotic blends for use on corals. In this way, they aim to utilize personalized-medicine techniques to help corals gain an ecological advantage over competitors such as harmful algae.

Jessica Else, editor-in-chief, can be reached at 245-0457 or jelse@thegardenisland.com.

Read the rest here:
Probiotics for the reef - Thegardenisland.com

Direct to Consumer (DTC) Genetic Testing Market Size was valued around USD 800 million in 2018 and is expected to witness lucrative growth from 2019 to 2025.

Rising adoption of genetic tests in various applications including cancer and various genetic disorders will augment the growth of direct to consumer genetic testing market over the forecast period. Currently developed DTC genetic tests allows customer to recognize chance of acquiring a genetic disease. Thus, growing adoption of DTC genetic testing for premature disease detection and identification of genetic diseases will boost the market growth over forecast timeline. However, the genetic tests are costly which may restrict the genetic testing market over forecast period.

Download the sample report to understand the market growth in Direct to Consume Genetic Testing :

https://www.insidemarketreports.com/sample-request/9/152718/direct-to-consumer-genetic-testing-markets

On the basis of test type the market is segregated into predictive testing, carrier testing, Ancestry & relationship testing, nutrigenomic testing and others. Predictive testing has potential to identify complicated disease which might be associated with the patient in future. Thus predictive testing can help in identifying the diseases ahead of time and suggest personalized medicine which aids to segmental growth of predictive testing market over the future.

Genetic testing market by technology is further divided into Targeted Analysis, Single Nucleotide Polymorphism (SNP) Chips, Whole Genome Sequencing (WGS). Targeted analysis is used to determine the defect in genes that are responsible for a particular disease. Targeted genotyping can precisely determine a persons genetic pool that encodes vital information regarding various disorders. Targeted analysis is less costly compared to rest of the test which will drive the adoption rate of this segment.

North America is anticipated to account for the largest share of the Global Genetic Testing Market. Increasing innovative technologies in genetic tests coupled with rising adoption of these tests will augment the growth of the market. Asia-Pacific is expected to show rapid growth in coming years. Increasing prevalence of chronic diseases will boost the APAC genetic testing market in forecast period.

By Test type

By Application

By Region

Company Coverage

Questions addressed in the report

Conclusion:

In this report, we had discussed the market situation of Direct to Consume Genetic Testing. As we know the world is going to be tech savvy, the demand of trending products and technologies is also increasing. This report can help to understand the business growth in the Direct to Consume Genetic Testing and new opportunities at new places.

Dont push the river; let the river flow!!

Hurry up! and grab the discount for this report

https://www.insidemarketreports.com/discount/9/152718/direct-to-consumer-genetic-testing-markets

For any type of research report, Contact us at:

Company Name: Inside Market Reports

Address: 1 Apache Way, Westford, Massachusetts 01886, USA

Email: [emailprotected]

Contact no: +1-617-230-0741

Follow this link:
Direct to Consumer (DTC) Genetic Testing Market Analysis, Evolving Opportunities, Industry Trends, Business Growth, Revenue And Forecast upto 2025 -...

OKLAHOMA CITY, June 3, 2020 /PRNewswire/ --Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors. Dr. Sakul has a distinguished track record in the development and commercialization of companion diagnostics, precision medicine, and pharmacogenomics. His wealth of experience and knowledge will support Progentec in its mission to improve health outcomes for people living with autoimmune diseases.

"Lupus is a difficult disease to diagnose and a lab-based testing is sorely needed to confirm its diagnosis," said Dr. Sakul. "I am delighted to join Progentec's Board in this important phase of the company's diagnostics development journey."

In addition to his R&D, clinical, and product expertise, Dr. Sakul has deep experience in regulatory policy. He is currently a member of California Gov. Newsom's Precision Medicine Advisory Council, and was previously an Advisory Board member for California Gov. Brown's Precision Medicine Advisory Committee. Dr. Sakul is also on the board of directors for the Personalized Medicine Coalition and serves on Luminex Corporation's Oncology Advisory Committee.

About Progentec Diagnostics, Inc.

Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

Forward-Looking Statements:

Statements contained herein that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

Contact:

Mohan Purushothaman

(973) 885-5242

[emailprotected]

SOURCE Progentec Diagnostics, Inc.

http://www.progentec.com

More here:
Precision Medicine and Diagnostics Expert Hakan Sakul, Ph.D., of Pfizer Joins the Progentec Board of Directors - PRNewswire

Fasten your seatbelts, folks, because the stock market has been on one heck of an emotional roller-coaster over much of the past four months. Initially, panic and uncertainty tied to the coronavirus disease 2019 (COVID-19) pandemic sent the broad-based S&P 500 down 34% in less than five weeks. But in the subsequent 11 weeks, we've witnessed roughly 80% of this initial drop clawed back by equities, with Wall Street appearing to enter a new bull market.

Although swoons in the stock market are inevitable, history has decisively shown that opportunistic long-term investors who buy during these periods of weakness tend to make money. It's never really a question of whether you should invest when a new bull market emerges, but where you should park your capital.

Assuming a new bull market has been established, the following four industries look set to thrive (and dominate) for a long time to come.

Image source: Getty Images.

One of the bigger beneficiaries of the COVID-19 pandemic is cybersecurity. To be perfectly clear, cybersecurity was already growing at a healthy pace well before the coronavirus shut down nonessential businesses across much of the country. But with more employees being forced to work remotely than ever before, the need to secure cloud-based data is taking on added importance. Essentially, COVID-19 took an existing trend and gave it a shot of adrenaline.

Hands down, my favorite company in this space is Palo Alto Networks (NYSE:PANW), which I pegged on April 9, 2020, as one of five stocks that could be a 10-bagger (i.e., deliver 1,000%-plus returns) by 2030.

Aside from the fact that enterprise cloud demand continues to pick up, Palo Alto benefits from the fact that it's pushing subscription and support-based solutionsas opposed to hardware. Subscriptions generate much better margins than hardware, and cash flow is far more predictable as Palo Alto is unlikely to see customer churn for what's effectively a basic-need service for any business.

Over the past year, Palo Alto's subscription and support revenue has grown to account for 68% of total sales, up from approximately 62% in the prior-year quarter.

Image source: Getty Images.

Building off of cybersecurity, the hottest thing since sliced bread in the new bull market is going to be anything having to do with cloud computing. This could mean the infrastructure players that are responsible for aiding businesses in creating their cloud, platform-as-a-service providers that allow enterprises to build, manage, and deploy applications, and software-as-a-service companies, which operate and sell ready-to-use apps for businesses and consumers.

Interestingly, some of the most prominent names in the cloud space are the United States' largest publicly traded companies: Amazon (NASDAQ:AMZN) with Amazon Web Services (AWS), Microsoft with Azure, and Alphabet with Google Cloud.

I don't see how investors can't get excited about Amazon in the new bull market. Even putting aside its e-commerce dominance, AWS continues to grow at about twice the pace of its retail/ad operations, and it produces considerably better margins. With Amazon's cloud services now accounting for 13.5% of total sales in Q1 2020 and a majority of its operating income, it's no wonder Wall Street expects a near-tripling in the company's operating cash flow by 2023.

Image source: Getty Images.

The new bull market will also feature an ongoing push toward personalized medicine. By personalized medicine, I'm referring to the idea of tailoring treatment for each individual rather than offering generalized medical solutions. Most personalized medicine leans on the increased use of technology, the cloud, and innovative new devices.

For example, another 10-bagger stock I singled out in April is Livongo Health (NASDAQ:LVGO), a provider of personalized health solutions. Using mountains of collected data and artificial intelligence, Livongo sends tips to members with diabetes in order to help them make meaningful behavioral changes that result in them living longer and healthier lives. It also doesn't hurt that Livongo's solutions can potentially work hand in hand with other wireless diabetes devices (e.g., insulin pumps), meaning patients don't have to leave the comfort of their homes to convey sensitive data to their physicians.

Maybe the best thing about Livongo Health and the personalized medicine push is that it's not all talk. Livongo's Diabetes member count doubled from the prior-year quarter to more than 328,000, and it's already generated two consecutive quarters of profitability despite significant reinvestment into its solutions.

If Livongo is already turning the corner to profitability with less than 1% of U.S. diabetes market share, just imagine its potential when it expands to treat other chronic illnesses, like hypertension.

Image source: Getty Images.

Finally, look for the Internet of Things (IoT) to finally realize its full potential in the new bull market. By IoT, I'm talking about wireless devices being able to connect and communicate with one another and data centers. Examples might include a smart thermostat that learns your heating and cooling preferences to conserve energy usage in your home, or an automobile that automatically reorders a defective or soon-to-be-defective component.

It's not uncommon for Wall Street and investors to overestimate the impact of new technology and be left disappointed. This is sort of what happened with IoT stocks in the latter half of the 2010s. But with an increased reliance on work-from-home, the cloud, and even personalized medicine, the value of IoT is rising like never before.

To build off of the previous industry (personalized medicine), DexCom (NASDAQ:DXCM) is the perfect example of IoT in action. Dexcom, which happens to have a deal in place with Livongo Health, is a producer of continuous glucose monitoring devices for diabetics. DexCom's devices can provide patients with real-time blood-glucose levels, communicate with insulin pumps to administer or hold off on the administration of insulin, and aid in producing reports that can be sent to a primary care provider.

IoT has applications in virtually every industry, and the new bull market should showcase that fact.

See the original post:
4 Industries That'll Thrive in the New Bull Market - Motley Fool

New York, June 09, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Humanized Mouse Model Market 2020-2024" - https://www.reportlinker.com/p05048523/?utm_source=GNW Our reports on humanized mouse model market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising focus on preventing the spread of pandemics and innovative applications. In addition, rising focus on preventing the spread of pandemics is anticipated to boost the growth of the market as well. The humanized mouse model market analysis includes product segment and geographic landscapes

The humanized mouse model market is segmented as below: By Product Genetically humanized mouse model Cell-based humanized mouse model

By Geographic Landscapes North America Europe Asia ROW

This study identifies growing adoption of personalized medicine as one of the prime reasons driving the humanized mouse model market growth during the next few years. "The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our humanized mouse model market covers the following areas: Humanized mouse model market sizing Humanized mouse model market forecast Humanized mouse model market industry analysis"

Read the full report: https://www.reportlinker.com/p05048523/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Follow this link:
The Global Humanized Mouse Model Market is expected to grow by $ 74.72 million during 2020-2024 progressing at a CAGR of 12% during the forecast...

The following discussion and analysis should be read together with our unauditedcondensed consolidated financial statements and related notes thereto set forthin this Quarterly Report on Form 10-Q as well as our Annual Report on Form 10-Kfor the year ended December 31, 2019.This Form 10-Q contains "forward-looking statements" that indicate certain risksand uncertainties, many of which are beyond our control. Actual results coulddiffer materially and adversely from those anticipated in such forward-lookingstatements as a result of certain factors, including those set forth below andelsewhere in this report. Important factors that may cause actual results todiffer from projections include: We may not be able to continue operating without additional financing; Current negative operating cash flows; The terms of any further financing, which may be highly dilutive and may include onerous terms; Significant debt repayments due between June and September 2020, which the Company will likely need to extend or

restructure, with

associated with

pandemic, which

Our precision medicine business, conducted in our Helomics division, iscommitted to improving the effectiveness of cancer therapy using ourproprietary, multi-omic tumor profiling platform, one-of-a-kind database ofhistorical tumor data, and the power of AI to build predictive models of tumordrug response.

Contract Research Organization (CRO) and AI-Driven Business

Patient enrichment & selection for trials

Clinical trial optimization

Via our Helomics subsidiary, we offer a group of clinically relevant,cancer-related tumor profiling and biomarker tests for gynecological cancersthat determine how likely the patient is to respond to various types ofchemotherapy and which therapies might be indicated by relevant tumorbiomarkers.

Skyline Medical - The STREAMWAY System

STREAMWAY System Product Sales

We sell our medical device products directly to hospitals and other medicalfacilities using employed sales representatives, independent contractors anddistributors.

Comparison of three-month periods ended March 31, 2020 and March 31, 2019

Operations expense. Operations expense primarily consists of expenses related toproduct development and prototyping and testing in our current stage.

Liquidity and Capital Resources

Net cash used in operating activities was $2,972,981 and $2,048,653 for thethree months ended March 31, 2020 and March 31, 2019, respectively. Cash used inoperating activities increased in the 2020 period primarily because of theincrease in total operating expense and the additional costs related to theHelomics business.

Liquidity, Plan of Financing, and Going Concern Qualification

We have funded our operations through a combination of debt and equityinstruments including short term borrowings, and a variety of debt and equityofferings.

February 2020 Convertible Note

March 2020 Private Placement of Common Stock and Warrants

March 2020 Amendments to and Extensions of Promissory Notes

April 2020 Paycheck Protection Program

May 2020 Registered Direct Offering of Common Stock and Concurrent PrivatePlacement of Warrants

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet activities as defined in Item303(a)(4) of Regulation S-K.

Accounting Standards and Recent Accounting Developments

See Note 1 - Summary of Significant Accounting Policies to the unaudited,Condensed Consolidated Financial Statements of this Quarterly Report on Form10-Q for a discussion of recent accounting developments.

Edgar Online, source Glimpses

Link:
PREDICTIVE ONCOLOGY : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.com

OKLAHOMA CITY, June 3, 2020 /PRNewswire/ --Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, announced today that Hakan Sakul, Ph.D., Vice President and Head of Diagnostics at Pfizer, has joined the Progentec Board of Directors. Dr. Sakul has a distinguished track record in the development and commercialization of companion diagnostics, precision medicine, and pharmacogenomics. His wealth of experience and knowledge will support Progentec in its mission to improve health outcomes for people living with autoimmune diseases.

"Lupus is a difficult disease to diagnose and a lab-based testing is sorely needed to confirm its diagnosis," said Dr. Sakul. "I am delighted to join Progentec's Board in this important phase of the company's diagnostics development journey."

In addition to his R&D, clinical, and product expertise, Dr. Sakul has deep experience in regulatory policy. He is currently a member of California Gov. Newsom's Precision Medicine Advisory Council, and was previously an Advisory Board member for California Gov. Brown's Precision Medicine Advisory Committee. Dr. Sakul is also on the board of directors for the Personalized Medicine Coalition and serves on Luminex Corporation's Oncology Advisory Committee.

About Progentec Diagnostics, Inc.

Progentec is committed to improving access and health outcomes for patients in therapeutic areas with a high level of unmet need by combining clinically-validated diagnostic interventions with state-of-the-art digital technologies. Through collaborations with research institutions and health practitioners around the world, Progentec is working to reduce mortality and morbidity while improving care management and service delivery for chronic health conditions.

Forward-Looking Statements:

Statements contained herein that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release based on currently available information. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements.

Contact:

Mohan Purushothaman

(973) 885-5242

mpurushothaman@progentec.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/precision-medicine-and-diagnostics-expert-hakan-sakul-phd-of-pfizer-joins-the-progentec-board-of-directors-301070191.html

SOURCE Progentec Diagnostics, Inc.

Here is the original post:
Precision Medicine and Diagnostics Expert Hakan Sakul, Ph.D., of Pfizer Joins the Progentec Board of Directors - BioSpace

Precision medicine (PM) is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Personalized nanomedicine involving individualized drug selection and dosage profiling in combination with clinical and molecular biomarkers can ensure the maximal efficacy and safety of the treatment. The major hindrance toward the development of such therapies is the handling of the Big Data, to keep the databases updated. Robust automated data mining tools are being developed to extract information regarding genes, variations, and their association with diseases. Phenotyping, an integral part of PM, is aimed at translating the data generated at cellular and molecular levels into clinically relevant information.Precision Medicine Moves Care from Population-Based Protocols to Truly Individualized Medicine as President of the US announced the Precision Medicine Initiative in his 2015 State of the Union address. Under the initiative, medical care would transition from a one-size-fits-all approach to an individualized approach, in which data on each patients genomic makeup, environment, and lifestyle (the exposome) helps medical professionals tailor treatment and prevention strategies. To achieve the Precision Medicine Initiative mission statement, to enable a new era of medicine through research, technology, and policies that empower patients, researchers, and providers to work together toward development of individualized care, researchers and clinicians need vast and varied amounts of data and the technology to ensure that data is widely accessible and usable.

Browse Complete Report with TOC https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Insights Presented in the Report

Based on technology type, the market is fragmented into big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.Recent technological and analytical advances in genomics, have now made it possible to rapidly identify and interpret the genetic variation underlying a single patients disease, thereby providing a window into patient-specific mechanisms that cause or contribute to disease, which could ultimately enable the precise targeting of these mechanisms

Based on the market segment by application type, the market is segmented into oncology, respiratory diseases, central nervous system disorders, immunology, genetic diseases and others. With the advent of precision medicine, cancer treatment is moving from a paradigm in which treatment decision isprimarily based on tumor location and histology followed by molecular information to a new paradigm whereby treatment decisions will be primarily based on molecular information followed by histology and tumor location

Based on the market segment by end-user, the market is fragmented into hospitals & clinics, pharmaceuticals, diagnostic companies, Healthcare-IT firms and others. The precision medicine suppliers that understand technology and the goals of value-based healthcare can create value in the precision medicine value-chain by offering value-based solutions and platforms to interpret and connect data points. There are a number of technology companies who work in the field of precision medicine and more will be founded in the years to come

For better understanding on the market dynamics of Precision Medicine market, detailed analysis was conducted for different countries in the region including North America (United States, Canada, Mexico and Rest of North America), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, Australia, India and Rest of APAC), and Rest of World

Some of the major players operating in the market includeHoffmann-La Roche, Medtronic, Qiagen, Illumina, Abbott Laboratories, GE Healthcare, NanoString Technologies, bioMrieux SA, Danaher Corporation, and AstraZeneca

Request for Sample of the report https://univdatos.com/request_form/form/286

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends and opportunities prevailing in the industry.

Examination of industry attractiveness with the help of Porters Five Forces analysis

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Feel free to contact us for any queries https://univdatos.com/request_form/form/286

Customization Options:

Precision MedicineMarket can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

About us:

UnivDatos Market Insights (UMI), is a passionate market research firm and a subsidiary of Universal Data Solutions. We believe in delivering insights through Market Intelligence Reports, Customized Business Research, and Primary Research. We are a diverse group of some of the most talented people in the research landscape, who with their collective experience, help us drive our machine and creatively solve every business challenge of millennial organizations. Our team comprises of accomplished professionals from leading consulting environments and serve some of the significant Fortune 500 companies around the world.

Contact us:

UnivDatos Market Insights (UMI)

Email: [emailprotected]

Web: https://univdatos.com

Ph: +91 7838604911

Read this article:
Precision Medicine Market Industry Analysis, Size, Share, Growth, Trends, and Forecast 2020-2026 - 3rd Watch News

Like so many people across the United States and around the world, my colleagues and I at Celmatix feel deeply outraged by the brutal and senseless murders of Breonna Taylor, Ahmaud Arbery, and George Floyd. We stand in solidarity with the millions of people lifting their voices in protest and also join countless more in reflecting on what we can do to make this a turning point for racial inequality.

Inequality comes in many forms for People of Color, both here and abroad, but race-related health disparities are among the starkest and most resistant to progress. Being a Black female further amplifies these inequities, which is particularly troubling and ironic given the fact that Women of Color make up the majority of healthcare workers. Over the last few months, the COVID-19 pandemic has brought this unfortunate reality into even more clear focus.

An often-cited quote in the business world is you cant manage what you cant measure. At Celmatix, we have been working for over a decade to address critical gaps in data collection for womens health. This has included thinking outside of the bubble of traditional research metropolises like Boston and San Francisco, and expanding our research partnerships to reproductive health centers of excellence across the US and to biological repositories that allow us to reach women at community health centers and urban hospitals which serve women who may not have access to reproductive specialist care. In addition to investing in diversified data for our scientific and clinical research studies, weve also made significant investments in our Next Gen Womens Project, an ambitious two-year consumer research effort that interviewed or surveyed more than 4K millennial women to understand how their healthcare needs differ from earlier generations of women and to discern their attitudes concerning their reproductive health and fertility. As part of this research, we had the privilege of collaborating withthe Black Womens Health Imperative, Womens Health Magazine, and Oprah Magazineto better understand why Black women are facing higher infertility rates, greater stigma around reproductive challenges, and larger barriers to accessing fertility care.

Taken together, the picture is clear: the disparities we see in womens health funding, research, delivery, innovation, data collection, and outcomes are consistently amplifiedmultifoldfor women of color.As we reflect on policy changes that could have an outsized impact on addressing centuries of racial inequality in the US, we can think of no better place to start than with improving the health of black women.

Black Womens Health ImperativeThe countrys first nonprofit organization created by Black women to help protect and advance the health and wellness of Black women and girls

Black Mamas Matter AllianceThe alliance helps advocate for better legislation to reduce black maternal mortality, highlights necessary areas of research and spreads information about the social determinants of health that influence outcomes like traumatic birth or maternal and infant mortality.

Sister SongSisterSong is a Southern-based, national membership organization; its purpose is to build an effective network of individuals and organizations to improve institutional policies and systems that impact the reproductive lives of marginalized communities

Fertility for Colored GirlsProvides services for underserved Black women and couples. This includes educational programming about treatment options, resources to connect with counselors, financial grants, and monthly support group meetings hosted by seven different chapters across the country,

Linda Villarosa:Journalist

Patrice Peck:Journalist

Laurie Zephyrin, MD:Obgyn, VP Health Care Delivery System Reform at Commonwealth Fund

Reproductive Injustice: Racism, Pregnancy, and Preterm Birth.Davis DA.NY: NYU Press:

Black Lives Matter: Claiming a Space for Evidence-Based Outrage in Obstetrics and Gynecology.Eichelberger KY, Doll K, Ekpo GE, Zerden ML. Am J Public Health. 2016 Oct;106(10):17712. doi: 10.2105/AJPH.2016.303313.

Key Facts on Health and Health Care by Race and Ethnicity,Samantha Artiga and Kendal Orgera. KFF, Published: Nov 12, 2019

When Maternity Wards in Black Neighborhoods Disappear:NYT, Kelly Glass, May 4, 2020

A Preventable Cancer is on the Rise in Alabama:The New Yorker, Eyal Press, March 30, 2020

This article originally appeared on Celmatix, where Dr.Piraye Yurttas Beim, who is also an EndoFound Board Member, is the founder. If you have additional data to share or organizations you would like us to highlight here, please reach out to atinfo@celmatix.comor info@endofound.org. Please also check back as we plan to expand on this list in the coming weeks. And finally, we urge you to help us raise awareness about this important issue by sharing this in your networks.

See the original post here:
The Disparities In Healthcare For Black Women | EndoFound - Endometriosis Foundation of America - The Blossom

New York, June 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Digital Genome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography" - https://www.reportlinker.com/p05908643/?utm_source=GNW However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Digital genome is a complete digital set of genetic material that present in an organism or a cell.Digital genome technology deals with genes and their functions to find the causes behind the chronic diseases and also to fix them.

The technology is associated with the advancements that help to make healthcare more personal and more effective for the treatment.Digital genome facilitates instant access to trait sequences to resolve unending custom queries.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the worlds largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical.The UK has already developed the largest genome database in the world through the 100,000 Genomes Project.

Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently. Moreover, in August 2018, Boston, a Massachusetts-based company, announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the companys mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death. Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

The World Health Organization (WHO), Food and Drug Administration (FDA), NHS (National Health Service), and Centers for Disease Control and Prevention are some of the major primary and secondary sources referred for preparing this report.Read the full report: https://www.reportlinker.com/p05908643/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the article here:
Digital Genome Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product ; Application ; End User, and Geography - GlobeNewswire

This Patch article is sponsored by Summit Physical Therapy Inc.

Summit Physical Therapy, founded in 1988, is an independent, physical therapist-owned, private practice with a convenient location serving Union, Essex and Morris counties. In a world of medicine dictated by corporations, Summit Physical Therapy stays true to its roots with treatment provided only by licensed physical therapists.

In this environment, it is able to provide the personalized treatment that every patient deserves, as well as develop relationships that last longer than treatment. From exercising to stretching, the practice teaches you exactly how to manage your condition so you can live a happy and pain-free life.

John V. Scioscia, president of Summit Physical Therapy, let Patch in on the secrets to his 30-plus years of success in the business, as well as how the practice is providing virtual treatment throughout the COVID-19 pandemic.

Patch: How long have you been doing business in town?

Scioscia: Summit Physical Therapy has been operating since 1988. My wife and I have lived in Summit now for the past 35 years. We raised our children here and have stuck around even after they left. The whole family has been very involved in the community, between sports, my involvement in various boards and organizations, and my wife previously working at Lincoln-Hubbard Elementary School.

Patch: What attracted you to the line of work you're in, and how did you get started?

Scioscia: I have always had a passion for science and fixing things. As a child, this led me in the direction of medicine. I eventually wound up being recruited to Boston University for wrestling with the intention to become a physician. Over the course of my athletic career at Boston, I became involved with physical therapy and athletic training. After college, I started my career in professional sports, but I soon realized I wanted a life that allowed for more time at home with my family. I founded Summit Physical Therapy, and the rest has been amazing.

Patch: If you had to sum up your business mission in five words to a stranger, what would those words be?

Scioscia: Honest. Independent. Experienced. Skilled. Community.

Patch: What's the most satisfying part of your job?

Scioscia: In general, the most satisfying part of my job is helping people. There are some instances when a patient is dealing with a more difficult or complex case and confides that we have made a breakthrough. That is a special moment. As a physical therapist, I get a lot of time to truly invest in a patient's well-being. Making that personal connection and building trust with someone who needs it most is particularly satisfying.

Patch: How would you say your business or organization distinguishes itself from the others?

Scioscia: The physical therapy industry as a whole has changed in recent years. Most have adopted a "team" model, where your care is delivered by numerous aides, technicians and assistants, putting the therapist in more of a supervisory role. At Summit Physical Therapy, your care is delivered entirely by physical therapists. We pride ourselves in being involved in every part of the rehab process. We even take care of sanitizing surfaces ourselves. Nothing is outsourced. Neighbors caring for neighbors. We have also maintained the same staff. Aside from bringing on a new therapist two years ago, our entire staff has worked here for over 20 years. It is hard to say that about any company, let alone a PT clinic. You definitely know someone who has been treated by our therapists.

Patch: What's the best piece of advice you've ever been given when it comes to success?

Scioscia: "You are either moving forward or moving backward." This has applied to how we manage the business but is also applicable to our patients and athletes.

Patch: Are there any new projects or endeavors you're working on that you're extra excited about?

Scioscia: Interestingly enough, we had been planning to start offering telehealth services starting the summer of 2020 prior to this COVID-19 outbreak. Our goals were to provide an easier way for patients to receive care when they could only make it to the clinic on a less-than-optimal basis, provide PT for our patients who travel for business or vacation, provide a more-efficient method to monitor patients as they phase back into normal life after rehab, and to provide athletic program monitoring from a far with our Performance Therapy service.

Obviously, this pandemic moved our rollout date up by a few months, and we have now been practicing telehealth for over three months! Maintaining our theme of honesty, telehealth is not adequate to replace all in-clinic treatment, but is phenomenal for many treatments. We have seen great success with getting patients in for isolated treatments, if in acute or recent-onset pain, progressing to telehealth when symptoms are less irritable. For patients who are in lesser levels of pain, telehealth can be a great option even to start. We are currently offering free telehealth consultations to answer any questions and to help you find what treatment option is best for you.

Patch: Do you have any events coming up in your community?

Scioscia: In November 2019, we started hosting a lecture series at our clinic as well at a few local businesses. Since March, we have converted the series to webinars, which is not only awesome to maintain social distance but allows many more people to access the information from their home. Keep an eye on our Facebook and Instagram for the next webinar we host.

Patch: How can Patch readers learn more about your work and business?

Scioscia: Our website was designed less as a marketing tool and more as a source of information for our patients and the public. We have information on specific conditions, what to expect with PT page, therapist bios, and even a request for an appointment function. We are also on Facebook and Instagram.

Phone: 908-598-9009Email: physicaltherapysummit@gmail.com

More:
Summit Physical Therapy Offers Personalized Treatment To Patients - Patch.com

Market Scenario

Global in Vitro Fertilization market is expected to reach USD 847.8 Bn by 2026 at a CAGR of 10.5 % during the forecast period.

The Global in Vitro Fertilization market is segmented based on product, type of cycle, end-user, and region.

Request for Report Sample: https://www.trendsmarketresearch.com/report/sample/10296

By Product type Reagents, Equipment.By Type of Cycle Fresh Non-Donor IVF Cycles, Frozen Non-Donor IVF Cycles, Frozen Donor IVF Cycles, Fresh Donor IVF Cycles, By End User Hospitals & Research Laboratories, Cryobanks. By region North America & South America, Europe, Asia-Pacific and, Middle East & Africa

In vitro fertilization is a procedure in which egg from women ovary are removed and after that, the egg is fertilized with a sperm in a laboratory procedure, and then the fertilized egg is transferred into the women uterus. In vitro fertilization is used in the management of female infertility.

Major Market Drivers:

Rising rate of infertility Increasing in delayed pregnancies and raising awareness of personalized medicine. Surge in IVF success rate Unfavourable Reimbursement Scenario. Rise in disposable income worldwide.Restraint: High cost of treatment which is restraining this market. Less awareness level for IVF in developing countries which is another restraint of this market.

Request for Report Discount: https://www.trendsmarketresearch.com/report/discount/10296

Global In Vitro Fertilization Market

Strategic Developments in the Global In Vitro Fertilization Market:

In July 2018, Merck launched new products QBOX IVF. This product useful in data transfer between lab instrument and electronic medical record provider. It provides support healthcare professionals in fertility.

In February 2016, Adelaide biotech company, a reproductive health science company expanded IVF expertise into other DNA testing area by the launch of new product. This screening kits count the number of chromosomes in embryo to transfer in an IVFcycle.

Product Insights:Reagents and electrodes segment are expected to reveal exponential CAGR throughout the forecast period due to innovative product launches, and surge in IVF success rate unfavorable reimbursement scenario and rise in disposable income worldwide across the globe.

The North American region is playing the principal role in the global in vitro fertilization market due to the presence of several leading players. Though, Asia-Pacific will be the second major market in the proximate future. The presence of innovative medical advanced technology, a rising rate of infertility, increasing in delayed pregnancies and rising awareness on personalized medicine in the region.Scope of the Global In Vitro Fertilization Market Report

Global In Vitro Fertilization Market, by Product

Reagents EquipmentGlobal In Vitro Fertilization Market, by Type of Cycle

Fresh Non-donor IVF Cycles Fresh donor IVF cyclesGlobal In Vitro Fertilization Market, by End Users

Hospitals & Research Laboratories Cryobanks OthersGlobal In Vitro Fertilization Market, by Instrument

Incubators Cryosystem Cabinet Ovum Aspiration Pump Sperm Aspiration Pump Micromanipulator OthersGlobal In Vitro Fertilization Market, by Technology

Intra-cytoplasmic Sperm Injection (ICSI) Preimplantation Genetic Diagnosis (PGD)Global In Vitro Fertilization Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaGlobal In Vitro Fertilization Market Key Players

Groupe Clinique Ambroise Par amedes MVZ Cologne GmbH AMP Center St Roch, AVA International Clinic Scanfert Bangkok IVF center Betamedics Biofertility Center Bloom Healthcare Bourn Hall Fertility Center Cardone & Associates Reproductive Medicine & Infertility Cook Medical Inc. Coopersurgical Inc. Hamilton Thorne, Inc. Irvine Scientific Laboratoire CCD Merck KGaA Nidacon International AB Nikon Corporation Thermo Fisher Scientific Inc. Vitrolife AB

Full View of Report Description: https://www.trendsmarketresearch.com/report/analysis/MMR/global-in-vitro-fertilization-market

View original post here:
In Vitro Fertilization Market Industry Insights, Trends and Forecast up size 2026 - Cole of Duty

BioSpectrum Asia spoke to Francis Van Parys, Vice-President Commercial, Asia-Pacific, Cytiva (Formerly GE Life Sciences), Seoul, South Korea

The UK headquartered Cytiva is a $3.3 billion global life sciences leader with nearly 7000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Cytiva announced the collaboration with Takara Bio to develop DNA vaccine to confront the virus in Japan, on May 21. BioSpectrum Asia spoke to Francis Van Parys, Vice-President Commercial, Asia-Pacific, Cytiva (Formerly GE Life Sciences), Seoul, South Korea, who is responsible for providing transformational technologies in biopharmaceutical research, manufacturing and diagnostics to Cytiva customers and partners in the life sciences industry in China, India, Japan, Korea, ASEAN and Australia & New Zealand, for his major plans in store and his plans to enhance growth within the APAC region for the company.

Edited excerpts-

What are the major plans in store for Cytiva? Any new segments to be explored?

Cytiva offers the same high-quality services as we did when we were part of GE Healthcare Life Sciences. It shouldnt be overlooked that we are already a life sciences global leader and we expect our significant growth of recent years to continue. We have been at the forefront of innovation and development of areas such as protein purification, single-use technology and cell and gene therapies.

Cytiva will benefit from being a newly-created organization that is already a global life sciences leader. We have market leading brands such as KTA, Amersham, HyClone and Whatman, among others. We also have more than 100,000 systems in use globally. We will continue innovating from within and working with our customers to develop next generation solutions.

One area where we want to and must do better is sustainability. This is a challenge and opportunity for any organization operating today and one that Cytiva takes very seriously. We dont want to be just compliant in sustainability terms, we want to lead the industry. We will be focusing on areas such as GHG emission, use of plastics, packaging, water management and societal impact among other areas.

How do you plan to enhance your growth within the APAC region?

Asias Economies are seeing rapid growth in past decades meanwhile it suffers for the increases in cardiac disease, cancer and diabetes are subsequently anticipated, driven by increased life expectancy and lifestyle changes. Biotherapeutics are, and will remain, in the forefront of curing many of these diseases and improving the quality of lives across Asia.

Cytiva is well positioned to support the growth in protein-based therapeutics and future treatments, such as cell and gene therapies. Additionally, as the global healthcare system rapidly moves toward more personalized medicine, Cytiva will work with our customers to ensure we are developing the right tools and technologies to ensure efficient manufacturing of novel therapeutics.

How is Cytiva contributing to this fight against COVID-19?

The COVID-19 crisis has brought together the scientific community like never before. Our global team is helping to accelerate the work of researchers, developers, and manufacturers of diagnostics and vaccines, to bring access to much-needed solutions for COVID-19.

In Asia, we just announced the collaboration with Takara Bio to develop DNA vaccine to confront the virus in Japan, on May 21. Genedrive: PCR assay to detect SARS-CoV-2; Sona Nanotech: rapid response lateral flow test; Avacta: Affimer-based point-of-care rapid screening test and University of Queensland: vaccine

What will be the impact of this pandemic on the global economy? How is Cytiva preparing itself?

Cytivas number one priority is the health and safety of our employees and our customers. We are working closely with local governments, and world health authorities to actively monitor the outbreak and take all necessary precautions. We are prepared to walk alongside our customers to help ensure continuity of business, stay connected virtually for support, and provide solutions in this time of need.

The pandemic should not derail us from our key mission, which is to support the worlds development of new technologies and the manufacturing of existing drugs, which are so much important to the diabetes patient, or the cancer patient, or the young child that needs a vaccine. To achieve this mission, you have to shuffle, because suddenly you have to prioritize particular initiatives that you didn't have in mind at all two months ago. We have a task force with special focus on the COVID-19 coronavirus, like we did when Ebola and SARS were global pandemics. This allows us to rapidly respond to the needs of our customers.

Cytiva has comprehensive crisis management andsecurity of supplyprograms in place. We are committed to fulfilling customer orders and regularly adjust our manufacturing output to respond to market demands, while ensuring our operations and service capabilities continue safely. We are also in regular contact with our suppliers regarding their business continuity plans to help minimize disruption of the flow of materials into our manufacturing facilities.

Ankit Kankar

ankit.kankar@mmactiv.com

Follow this link:
The COVID-19 crisis has brought together the scientific community like never before - BSA bureau

QY Research has published a new report on the global Targeted Biomarker market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, The analysts have clarified every part of the market exhaustive fastidious research and full focus to each point. This report gives additional information on statistical data to assist readers with understanding the entire market. This report offers a clear understanding of the present as well as future scenario of the global Targeted Biomarker industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Targeted Biomarker production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Targeted Biomarker market include _ bioMerieux, IntegraGen, Myriad Genetics, Protagen, Qiagen, PerkinElmer, Merck Millipore, Bio-Rad Laboratories, Enzo Biochem, EKF Diagnostics, Meso Scale Diagnostics, LLC. Targeted Biomarker Breakdown Data by Type

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1456215/global-targeted-biomarker-market

Segmental Analysis

The report has classified the global Targeted Biomarker industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Targeted Biomarker manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Targeted Biomarker industry.

Global Targeted Biomarker Market Segment By Type:

, Safety biomarker, Efficacy biomarker, Validation biomarker Targeted Biomarker Breakdown Data by Application,

Global Targeted Biomarker Market Segment By Application:

Diagnostics development, Drug discovery & development, Personalized medicine, Disease risk assessment, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Targeted Biomarker industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Targeted Biomarker market include _ bioMerieux, IntegraGen, Myriad Genetics, Protagen, Qiagen, PerkinElmer, Merck Millipore, Bio-Rad Laboratories, Enzo Biochem, EKF Diagnostics, Meso Scale Diagnostics, LLC. Targeted Biomarker Breakdown Data by Type

Key questions answered in the report:

For Discount, COVID-19 Impact, Customization in the Report: https://www.qyresearch.com/customize-request/form/1456215/global-targeted-biomarker-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Targeted Biomarker Revenue1.4 Market Analysis by Type1.4.1 Global Targeted Biomarker Market Size Growth Rate by Type: 2020 VS 20261.4.2 Safety biomarker1.4.3 Efficacy biomarker1.4.4 Validation biomarker1.5 Market by Application1.5.1 Global Targeted Biomarker Market Share by Application: 2020 VS 20261.5.2 Diagnostics development1.5.3 Drug discovery & development1.5.4 Personalized medicine1.5.5 Disease risk assessment1.5.6 Others 1.6 Study Objectives 1.7 Years Considered 2 Global Growth Trends by Regions2.1 Targeted Biomarker Market Perspective (2015-2026)2.2 Targeted Biomarker Growth Trends by Regions2.2.1 Targeted Biomarker Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Targeted Biomarker Historic Market Share by Regions (2015-2020)2.2.3 Targeted Biomarker Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Top Trends 2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Targeted Biomarker Market Growth Strategy2.3.6 Primary Interviews with Key Targeted Biomarker Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Targeted Biomarker Players by Market Size3.1.1 Global Top Targeted Biomarker Players by Revenue (2015-2020)3.1.2 Global Targeted Biomarker Revenue Market Share by Players (2015-2020)3.1.3 Global Targeted Biomarker Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Targeted Biomarker Market Concentration Ratio3.2.1 Global Targeted Biomarker Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Targeted Biomarker Revenue in 20193.3 Targeted Biomarker Key Players Head office and Area Served3.4 Key Players Targeted Biomarker Product Solution and Service3.5 Date of Enter into Targeted Biomarker Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Targeted Biomarker Historic Market Size by Type (2015-2020)4.2 Global Targeted Biomarker Forecasted Market Size by Type (2021-2026) 5 Targeted Biomarker Breakdown Data by Application (2015-2026)5.1 Global Targeted Biomarker Market Size by Application (2015-2020)5.2 Global Targeted Biomarker Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Targeted Biomarker Market Size (2015-2020)6.2 Targeted Biomarker Key Players in North America (2019-2020)6.3 North America Targeted Biomarker Market Size by Type (2015-2020)6.4 North America Targeted Biomarker Market Size by Application (2015-2020) 7 Europe7.1 Europe Targeted Biomarker Market Size (2015-2020)7.2 Targeted Biomarker Key Players in Europe (2019-2020)7.3 Europe Targeted Biomarker Market Size by Type (2015-2020)7.4 Europe Targeted Biomarker Market Size by Application (2015-2020) 8 China8.1 China Targeted Biomarker Market Size (2015-2020)8.2 Targeted Biomarker Key Players in China (2019-2020)8.3 China Targeted Biomarker Market Size by Type (2015-2020)8.4 China Targeted Biomarker Market Size by Application (2015-2020) 9 Japan9.1 Japan Targeted Biomarker Market Size (2015-2020)9.2 Targeted Biomarker Key Players in Japan (2019-2020)9.3 Japan Targeted Biomarker Market Size by Type (2015-2020)9.4 Japan Targeted Biomarker Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Targeted Biomarker Market Size (2015-2020)10.2 Targeted Biomarker Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Targeted Biomarker Market Size by Type (2015-2020)10.4 Southeast Asia Targeted Biomarker Market Size by Application (2015-2020) 11 India11.1 India Targeted Biomarker Market Size (2015-2020)11.2 Targeted Biomarker Key Players in India (2019-2020)11.3 India Targeted Biomarker Market Size by Type (2015-2020)11.4 India Targeted Biomarker Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Targeted Biomarker Market Size (2015-2020)12.2 Targeted Biomarker Key Players in Central & South America (2019-2020)12.3 Central & South America Targeted Biomarker Market Size by Type (2015-2020)12.4 Central & South America Targeted Biomarker Market Size by Application (2015-2020) 13Key Players Profiles13.1 bioMerieux13.1.1 bioMerieux Company Details13.1.2 bioMerieux Business Overview and Its Total Revenue13.1.3 bioMerieux Targeted Biomarker Introduction13.1.4 bioMerieux Revenue in Targeted Biomarker Business (2015-2020))13.1.5 bioMerieux Recent Development13.2 IntegraGen13.2.1 IntegraGen Company Details13.2.2 IntegraGen Business Overview and Its Total Revenue13.2.3 IntegraGen Targeted Biomarker Introduction13.2.4 IntegraGen Revenue in Targeted Biomarker Business (2015-2020)13.2.5 IntegraGen Recent Development13.3 Myriad Genetics13.3.1 Myriad Genetics Company Details13.3.2 Myriad Genetics Business Overview and Its Total Revenue13.3.3 Myriad Genetics Targeted Biomarker Introduction13.3.4 Myriad Genetics Revenue in Targeted Biomarker Business (2015-2020)13.3.5 Myriad Genetics Recent Development13.4 Protagen13.4.1 Protagen Company Details13.4.2 Protagen Business Overview and Its Total Revenue13.4.3 Protagen Targeted Biomarker Introduction13.4.4 Protagen Revenue in Targeted Biomarker Business (2015-2020)13.4.5 Protagen Recent Development13.5 Qiagen13.5.1 Qiagen Company Details13.5.2 Qiagen Business Overview and Its Total Revenue13.5.3 Qiagen Targeted Biomarker Introduction13.5.4 Qiagen Revenue in Targeted Biomarker Business (2015-2020)13.5.5 Qiagen Recent Development13.6 PerkinElmer13.6.1 PerkinElmer Company Details13.6.2 PerkinElmer Business Overview and Its Total Revenue13.6.3 PerkinElmer Targeted Biomarker Introduction13.6.4 PerkinElmer Revenue in Targeted Biomarker Business (2015-2020)13.6.5 PerkinElmer Recent Development13.7 Merck Millipore13.7.1 Merck Millipore Company Details13.7.2 Merck Millipore Business Overview and Its Total Revenue13.7.3 Merck Millipore Targeted Biomarker Introduction13.7.4 Merck Millipore Revenue in Targeted Biomarker Business (2015-2020)13.7.5 Merck Millipore Recent Development13.8 Bio-Rad Laboratories13.8.1 Bio-Rad Laboratories Company Details13.8.2 Bio-Rad Laboratories Business Overview and Its Total Revenue13.8.3 Bio-Rad Laboratories Targeted Biomarker Introduction13.8.4 Bio-Rad Laboratories Revenue in Targeted Biomarker Business (2015-2020)13.8.5 Bio-Rad Laboratories Recent Development13.9 Enzo Biochem13.9.1 Enzo Biochem Company Details13.9.2 Enzo Biochem Business Overview and Its Total Revenue13.9.3 Enzo Biochem Targeted Biomarker Introduction13.9.4 Enzo Biochem Revenue in Targeted Biomarker Business (2015-2020)13.9.5 Enzo Biochem Recent Development13.10 EKF Diagnostics13.10.1 EKF Diagnostics Company Details13.10.2 EKF Diagnostics Business Overview and Its Total Revenue13.10.3 EKF Diagnostics Targeted Biomarker Introduction13.10.4 EKF Diagnostics Revenue in Targeted Biomarker Business (2015-2020)13.10.5 EKF Diagnostics Recent Development13.11 Meso Scale Diagnostics, LLC.10.11.1 Meso Scale Diagnostics, LLC. Company Details10.11.2 Meso Scale Diagnostics, LLC. Business Overview and Its Total Revenue10.11.3 Meso Scale Diagnostics, LLC. Targeted Biomarker Introduction10.11.4 Meso Scale Diagnostics, LLC. Revenue in Targeted Biomarker Business (2015-2020)10.11.5 Meso Scale Diagnostics, LLC. Recent Development 14Analysts Viewpoints/Conclusions 15Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See original here:
Targeted Biomarker Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Cole of Duty

Other Applications

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Personalized Medicine market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=254994&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=254994&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Originally posted here:
Personalized Medicine Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty

Abraham Maslow said in 1966, I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail. This mentality known as the Law of the Instrument indicates that people tend to rely on the tool with which they are most familiar.

In a healthcare setting, that can translate into only using traditionally trained medical professionals to handle every situation, but in reality, some issues require a collaborative approach that includes other skills and experience. This is particularly relevant when it comes to addressing social determinants of health (SDoH).

Social determinants of health can include many things: food, housing and transportation insecurities; lifestyles, locations and surroundings; social isolation; and other factors that prevent people from achieving and maintaining good health. Non-clinical influences like these can drive up to 80% of clinical outcomes, affecting an individuals ability to be healthy.

In other words, it takes more than the latest treatments to keep people healthy. Much work is being done to address social determinants at the public health level, but these factors must also be addressed at the patient level. The paradox about population health is that its all about individuals and using a collaborative approach can be the key to success.

Why the Collaborative Approach WorksStudies indicate that patients who perceive their providers as more empathetic tend to get better more quickly, and experience less severe symptoms. Yet providers sometimes lack the capacity to treat patients holistically, or the data and insights to understand why a patient isnt taking their medicine, even though insights into social barriers can guide how providers should interact with patients.

Educating a patient is helpful, but typically not effective at changing behavior, especially when social factors are at work. Additionally, people trained in the medical field are not also trained and resourced to deliver interventions involving social factors.

This is where an interdisciplinary team approach can help to improve population health by addressing social determinants at the individual level. The best approach to care involves a team that includes a range of medical professionals, social workers, behavioral health specialists and community health coaches, all working together to formulate and deliver a comprehensive support plan tailored to each patients priorities and needs.

Instead of telling patients what to do, local care teams can work with patients to understand their barriers, such as lack of transportation or housing insecurity, and tap local resources to reduce or remove them. By simply asking the right questions, community health coaches can get much more tactical and concrete about supporting the individual and tailoring treatment support plans.

Additionally, these coaches often live in the same community and understand the context of peoples lives, which improves communication and creates trust. In fact, Medicaid members who receive community-based services are less likely to be admitted to the ER or as an inpatient in a hospital. During one-on-one interactions, community health specialists are well-positioned to understand the social roadblocks to access care and adhering to treatment plans.

A collaborative team is ideally suited to assess the social and environmental factors impacting a persons health, identify barriers of care, and create a personalized support plan that may include services such as behavioral health support, patient advocacy, and remote monitoring technology to remove those barriers and improve care plan adherence.

The Four Components of SuccessA successful strategy to address social determinants of health comprises four components:

Analytics: In any population health intervention, the team needs to identify through stratification who is at the greatest risk, to properly titrate the resource intensiveness of an intervention. If you try to intervene equally with everyone, your efforts (and funds) will be spread too wide and too thinly.

Using analytics on the front end can ensure that the people with the highest risk are receiving more intensive treatments. Healthcare teams can look to existing data sets like consumer marketing data, which often is a treasure trove of information on factors that affect health such as transportation, housing issues and financial stress. For example, data can reveal if an individual lives alone, owns a car, or lives near public transportation all factors that impact a persons ability to follow through with their care plan. These insights can be integrated with data on medical risk and cost of care before the amalgamated data set is stratified.

A multidisciplinary support team: As stated, for social determinants to be addressed on an individual level requires an integrated team of both clinical and social support experts and community-based coaches are essential contributors.

The right toolbox from which to draw: There are existing toolboxes of interventions for housing, food insecurity and stress management, and the care team should recognize what needs to be addressed and draw from existing strategies to address healthcare at the social level. Interventions that mitigate the social stressors impacting an individual around the clock provide the greatest health benefits.

Respect for the individuals priorities: A population health team must have the flexibility to prioritize what the individual sees as the greatest issue. For example, a homeless individual might have a substance use disorder (SUD). Typically, people with SUD cannot get into housing until they are in recovery; however, if the individual is not ready to work on their recovery, but does see stable housing as a stepping stone toward recovery, that should be respected so work first on what theyre ready to work on.

A Better Approach to Addressing Population HealthWhile the use of multidisciplinary teams can involve significant changes to work practices and organizational arrangements, providing community-based resources is essential to addressing social barriers that affect health and wellness.

By understanding the social factors that can impact patient wellness, and employing a collaborative approach to individual care, payers, providers and patients will reap the benefits of more successful outcomes improving population health overall.

Photo: marchmeena29, Getty Images

See the original post here:
The paradox of population health: Focus on personalized support for the greatest impact - MedCity News

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its robust menu of ready-to-use Simoa kits to include tau phosphorylated at threonine 181 (p-tau181), a highly specific biomarker for the study of Alzheimers disease pathology, in cerebral spinal fluid (CSF), serum and plasma. A growing body of research, including work published recently in The Lancet Neurology, suggests that the biomarker could prove critical to predicting Alzheimers disease progression and differentiating the disease from other neurodegenerative disorders. Moreover, an ultra-sensitive, blood p-tau181 assay may hold the key to advancing preventative care for the disease in clinics and via homecare sampling through a simple, cost-effective blood-based screening that can deliver an early, objective diagnosis. These findings and details on how researchers can gain early access to Quanterix new commercial assay through the Simoa Accelerator Laboratory, will be discussed during an upcoming Powering Precision Health (PPH) Think Tank Webinar taking place at 10 a.m., EDT on June 3, 2020.

Biomarkers continue to play an invaluable role in understanding how neurological diseases manifest, progress and respond to treatment, said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix. Building on years of innovation and a proven track record for successfully commercializing ultra-sensitive assays that disrupt markets and drive innovative breakthroughs forward, our p-tau181 version 2 assay kit offers researchers unrivaled visibility and specificity into this revolutionary marker in serum and plasma. The exquisite sensitivity of Simoa uniquely positions us to deliver on the promise of p-tau181 to pave new pathways in Alzheimers disease exploration, just as our neurofilament light chain (Nf-L) assay has transformed research for other neurological diseases. In particular, the impact of a high-definition, blood-based Simoa assay that rivals traditional CSF or PET scans could be revolutionary, with material potential for home sampling to enable early detection and development and approval of drug therapies desperately needed to improve outcomes for the millions of people living with Alzheimers disease today. This biomarker advance fits perfectly in our vision to transform reactive sick care' into proactive asymptomatic precision healthcare.

While deaths associated with other pervasive diseases such as heart disease have declined between 2000 and 2018, Alzheimers disease-related deaths have increased by 146 percent, according to the Alzheimers Association. Importantly, there is no objective test to diagnose the disorder, leading many physicians to rely solely on subjective cognitive assessments. As a result, many patients are not diagnosed until late in the diseases progression, after symptoms of cognitive decline, such as memory loss, begin to present. Even then, the disease can often be misdiagnosed for another neurodegenerative condition, such as frontotemporal dementia (FTD).

For years, researchers have studied the utility of biomarkers for understanding, detecting and monitoring Alzheimers disease. These efforts have been accelerated in large part by the PPH network, which has grown into a global epicenter for biomarker-enabled innovations to not only detect and treat, but ultimately, prevent disease. Resulting studies demonstrate the vast utility of proteins such as total tau and Nf-L. Researchers, doctors and pharmaceutical companies are now harnessing these biomarkers to see the disease earlier, monitor its progression and inform clinical decision making more effectively, and assess the viability of experimental therapies. Quanterix ultra-sensitive immunoassay technology, Simoa, which empowers single- and multi-plex detection of key biomarkers with 1000 times greater sensitivity than competing enzyme-linked immunosorbent assay (ELISA) solutions, is the driving technology behind much of this research. Among the most notable is a 2019 Nature Medicine paper that used Simoa to see signs of Alzheimers disease 16 years before symptoms through the high-definition detection of Nf-L. The technology has powered hundreds of similarly peer-reviewed journals over the years that demonstrate the potential for blood-based detection of the disease with equal or greater sensitivity as compared to CSF or PET biomarkers. Collectively, these studies create an influential body of research that advances the preventative care paradigm envisioned by PPH at its inception by supporting the utility of a non-invasive and easily administered blood test to detect Alzheimers disease before symptoms.

Today, emerging research suggests that p-tau181 could hold even greater diagnostic promise for Alzheimers disease, as it has proven capable of differentiating the condition from other forms of dementia with greater specificity than total tau. Leaders in the field of neurodegenerative disease research, such as the authors of The Lancet Neurology paper Professors Henrik Zetterberg, MD, PhD, and Kaj Blennow, MD, PhD, of the University of Gothenburg, believe blood p-tau181 has the potential to revolutionize Alzheimers disease research and patient care in much the same way that serum-based Nf-L has for multiple sclerosis (MS).These concepts further progress PPHs mission and vision to harness biomarkers for true precision health, with myriad implications that include improving understanding of the condition, enabling earlier diagnosis and intervention, informing more accurate long-term care, identifying clinical trial candidates earlier in the disease cascade and, subsequently, accelerating promising new therapies to market.

The latest installment of the PPH Think Tank series of webinars, entitled Novel p-tau181 Blood Immunoassay and the Future of Alzheimers Disease Research, will explore the vast opportunities associated with p-tau181 to revolutionize the way we approach disease and administer care. Specifically, the discussion will detail how an innovative immunoassay to measure p-tau181 in blood could accelerate efforts to establish a clinically relevant routine Alzheimers disease diagnostic test, and the potential high-definition detection via small volume blood samples creates for homecare precision health. Hrusovsky, together with Professors Zetterberg and Blennow, will break down the findings from the recent paper in The Lancet Neurology and examine how Simoa is powering exploration into uncharted territory as it pertains to Alzheimers disease detection, monitoring, treatment and prevention.

Were on the cusp of what could be an incredible new era for Alzheimers patients and those with a genetic predisposition to the disease, said Zetterberg. The ability to see dementia asymptomatically and moreover conclusively distinguish it as Alzheimers disease-induced could forever change the face of this condition. P-tau181 shows immense promise in this regard, which is augmented considerably when harnessed by a leader in detection like Quanterix.

Early findings from our work with p-tau181 are very encouraging, said Blennow. The biomarker is proving to be an exceptional new tool in our arsenal against Alzheimers disease. While CSF p-tau181 has been recognized as a highly valuable biomarker in Alzheimers disease pathology, the greater clinical benefit will come from our ability to effectively harness the marker in blood. The unprecedented specificity of p-tau181 paired with a highly sensitive technology like Simoa promises to broaden our knowledge of this devastating disease considerably, with monumental implications for patients and caregivers.

To register for the webinar, click here.

To learn more about how you can take advantage of our early access program for p-tau181 through the Accelerator Lab or pre-order your commercial kits, visit https://www.quanterix.com.

For more about Quanterix Simoa technology, visit https://www.quanterix.com/Simoa-bead-technology.

About Quanterix

Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health. The companys digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

About Powering Precision Health

Powering Precision Health is the world's first independent, non-profit organization dedicated to bringing the world's leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Founded by Kevin Hrusovsky, a widely acclaimed thought leader and visionary in life sciences and personalized medicine, Powering Precision Health is a movement that represents the intersection of new technological capabilities with the latest medical research. Its rooted in the science of precision medicine, which shows personalized treatments to be an increasingly more effective way to maximize drug efficacy and minimize toxicity. In addition to the impact environmental and lifestyle factors can have on minimizing disease triggers, precision health marks an evolution in the way we approach disease and aims to inspire a full healthcare transformation, from philosophy to approach to outcome. In an industry often plagued by skepticism and marred by false promises, PPH puts science first and brings together stakeholders that span from fundamental research to clinical practice, investors, policy makers, patient advocacy groups, and anyone who embraces the vision of Powering Precision Health. Featuring a distinguished keynote lineup of dignitaries, the Summit unveils groundbreaking approaches to prevention, early diagnosis, and next-generation treatments. Powering Precision Health is supported thanks to the generous contributions of sponsors from a wide range of companies and organizations committed to advancing precision health.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

See more here:
Quanterix Expands Menu of Ultra-Sensitive Neurology Assays with Simoa P-Tau181 V2 Kit for Improved Detection and Study of Alzheimer's Disease -...

New Jersey, United States, The Personalized Medicine Market report examines the market situation and prospects and represents the size of the Personalized Medicine market (value and volume) and the share by company, type, application and region. The general trends and opportunities of Personalized Medicine are also taken into account when examining the Personalized Medicine industry. Personalized Medicine The market report focuses on the following section: Analysis of the Personalized Medicine industry by transfer into different segments; the main types of products that fall within the scope of the report.

This Personalized Medicine market report is a complete analysis of the Personalized Medicine market based on an in-depth primary and secondary analysis. The scope of the Personalized Medicine market report includes global and regional sales, product consumption in terms of volume and value. The Personalized Medicine market report contains an estimate of revenue, CAGR and total revenue. The knowledge gathered in world trade Personalized Medicine is presented in figures, tables, pie charts and graphics.

Get | Research Sample Copy By Using Corporate Mail ID @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=COD&utm_medium=007

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Drivers and Restrains

The research report included analysis of various factors that increase market growth. These are trends, restrictions and drivers that change the market positively or negatively. This section also contains information on various segments and applications that may affect the market in the future. Detailed information is based on current trends and historical milestones. This section also includes an analysis of sales volume on the Personalized Medicine market and for each type from 2015 to 2026. This section mentions sales volume by region from 2015 to 2026. The price analysis is included in the report Type of year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020 and total price from 2015 to 2026.

An in-depth assessment of the restrictions contained in the report describes the contrast to the drivers and leaves room for strategic planning. The factors that overshadow the growth of the market are essential as they can be understood to design different phrases to take advantage of the lucrative opportunities that the growing Personalized Medicine market offers. In addition, information on the opinions of market experts was used to better understand the market.

Global Personalized Medicine Market: Segment Analysis

The research report contains certain segments such as application and product type. Each type provides revenue information for the 2015-2026 forecast period. The application segment also provides volume revenue and revenue for the 2015-2026 forecast period. Understanding the segments identifies the importance of the various factors that support Personalized Medicine market growth.

Global Personalized Medicine Market: Regional Analysis

The research report includes a detailed study of the regions of North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Personalized Medicine report was compiled after various factors determining regional growth, such as the economic, environmental, social, technological and political status of the region concerned, were observed and examined. Analysts examined sales, sales, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2015 to 2026. These analyzes help the reader understand the potential value of investments in a particular region.

Global Personalized Medicine Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. It helps the reader understand the strategies and collaborations that players focus on to fight competition in the market. The full report provides a significant microscopic overview of the Personalized Medicine market. Readers can identify manufacturers footprints by knowing manufacturers global earnings, manufacturers world market prices, and manufacturers sales for the 2015-2019 forecast period.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=COD&utm_medium=007

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

See the article here:
Personalized Medicine Market Growth Analysis by Size, Top Companies, Supply Demand, Trends, Demand, Overview and Forecast to 2026 - Cole of Duty